BioSpace News Archive

BetterLife Pharma Inc. is pleased to announce early positive in vitro results of its SARS-CoV-2 (“COVID-19”) anti-viral, recombinant human interferon alpha-2b (“rhIFN⍺2b” or “AP-003”), from the Dr. Stephen Barr Laboratory and state-of-the-art ImPaKT Facility at Western University (“UWO”). AP-003’s first proposed target indication is for people at higher risk to develop severe COVID-19 disease.

Corsair Pharma, Inc. today announced it will present at the LifeSci Partners Private Company Summer Symposium , to be held virtually July 21-23, 2021.

For the first year, Bayer earned a score of 100% in the 2021 Disability Equality Index (DEI) and was recognized for the third consecutive year as a Best Place to work for Disability Inclusion.

Ipsen (Euronext: IPN; ADR: IPSEY) and IRLAB (Nasdaq Stockholm; IRLAB A) today announced the signing of a licensing agreement, providing Ipsen exclusive worldwide development and commercial rights to mesdopetam, a novel dopamine D3-receptor antagonist.

During a celebration attended by strategic partners, business leaders and public officials, Nephron Pharmaceuticals Corporation CEO Lou Kennedy and Governor Henry McMaster announced the opening of Nephron Nitrile, a plant that will produce American-made, medical-grade nitrile gloves.

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2021 financial results after the market close on Thursday, August 5, 2021.

The human growth hormone is also referred to as somatotropin. It is a peptide hormone that is produced by the pituitary gland in the human body to regulate cell growth, metabolism, cell regeneration & repair, and reproduction for the development of the body.

TScan Therapeutics, Inc. (TScan), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the pricing of its initial public offering of 6,666,667 shares of common stock at a public offering price of $15.00 per share, for gross proceeds of $100.0 million,

Foundation Medicine, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne®Liquid CDx to be used as a companion diagnostic to aid in identifying patients with MET exon 14 skipping (METex14) in metastatic non-small cell lung cancer (NSCLC) for whom treatment with TABRECTA® (capmatinib) may be appropriate.

Heart block is the syndrome of the cardiovascular electrical unit, which monitors the rate of the heart and the rhythm.